Inspira Technologies Oxy Stock (NASDAQ: IINN)

Dernières nouvelles pour Inspira Technologies Oxy (NASDAQ:IINN) Stock

Inspira Technologies Oxy

Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares

Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. - Warrant

News

Petrobras CEO Reportedly Says Could Have Decision On Operator For Fertilizer Plants In Three Month's Time; Says Operation On Sergipe And Bahia's Fertilizer Plants To Resume By Year's End, Says Petrobras Wants More Control Over Chemical Firm Braskem; Says Petrobras To Make Effort To Cut Costs And Simplify Projects For 2026-2030 Strategic Plan

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barrington Research raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $112 to $125. Barrington Research analyst Alexander Paris maintained an Outperform rating. HealthEquity shares closed at $113.6 on Wednesday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from $100 to $115. Mizuho analyst David Bellinger maintained a Neutral rating. Five Below shares closed at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $124 to $130. Mizuho analyst Vijay Rakesh maintained an Outperform rating. Micron shares closed at $103.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $80 to $96. Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating. Dollar Tree Enterprise shares closed at $88.62 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased the price target for Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from $86 to $103. B of A Securities analyst Omar Dessouky maintained a Buy rating. Roblox shares closed at $91.05 on Wednesday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) price target from $107 to $122. Goldman Sachs analyst Kate McShane maintained a Buy rating. Five Below shares settled at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) price target from $134 to $145. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. BioNTech shares closed at $111.14 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) price target from $8 to $9. DA Davidson analyst Clark Wright maintained a Neutral rating. Sprinklr shares closed at $9.06 on Wednesday.  <a href="https://www.benzinga.com/quote/CXM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) from $23 to $22. Barclays analyst Adrienne Yih maintained an Overweight rating. Victoria&#8217;s Secret shares settled at $20.47 on Wednesday. <a href="https://www.benzinga.com/quote/VSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $52 to $59. Scotiabank analyst Brandon Bingham maintained a Sector Perform rating. Williams shares closed at $60.10 on Wednesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CRWD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MU/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png" alt="" class="wp-image-940314" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Price Target

Markets

Analyst Ratings

Trading Ideas

BNTX

DLTR

FIVE

RBLX

VSCO

Micron To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Petrobras CEO Chambriard Reportedly Says Africa Is Main Area Of Expansion For Firm Outside Of Brazil; Says Ivory Coast Extended Red Carpet For The Firm To Explore Country's Coast, Petrobras Will Participate In July Bidding Round For Exploratory Blocks In India; Petrobras Was Outbid By France's Total For Share Of Galp's Mopane Field;  Petrobras Still Expects To Be Invited To Help Develop Galp's Mopane Field; Petrobras' Next Five-Year Strategic Plan Proposes Drilling Of 30 Wells

The crypto market is under pressure as macro headwinds resurface. The ADP employment report indicates a slowdown in hiring, and renewed tariff uncertainty is <a href="https://www.benzinga.com/markets/economic-data/25/06/45768817/us-private-sector-hiring-slows-the-most-in-2-years-powell-must-now-lower-the-rate-trump-says">shaking investor sentiment</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$102,185.84</td>
<td>-2.6%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,537.69</td>
<td>-3.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$146.23</td>
<td>-6.1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.13</td>
<td>-4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1747</td>
<td>-8.1%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001258</td>
<td>-5.2%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume decreasing by 11.3%, with daily active addresses falling by 14.6%. Transactions greater than $100,000 are down from 11,969 to 11,237 in a single day. Exchanges netflows are down by 87.6%.</li>
<li>Coinglass data reports that 114,092 traders were liquidated in the past 24 hours, with a total liquidation value of $334.11 million.</li>
<li>Glassnode data <a href="https://x.com/glassnode/status/1930535675721380091">shows</a> Bitcoin&#8217;s largest holders have shifted back to accumulation after a brief distribution phase. All wallet cohorts are buying, with the most aggressive accumulation seen in the 10–100 BTC and sub-1 BTC groups, both hitting the maximum accumulation score of 1.0.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45800399/circle-surges-to-69-in-nyse-debut-raising-1-1b-as-investors-bet-on-stablecoins-going-mainstream">Circle Surges To $69 In NYSE Debut, Raising $1.1B As Investors Bet On Stablecoins Going Mainstream</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45800186/bitcoin-stock-strategy-buy-or-sell-what-technicals-reveal-for-michael-saylors-mstr">Bitcoin Stock Strategy— Buy Or Sell? What Technicals Reveal For Michael Saylor&#8217;s MSTR?</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45797385/bitcoin-becomes-corporate-treasury-favorite-eth-sol-xrp-far-behind-report">Bitcoin Becomes Corporate Treasury Favorite, ETH, SOL, XRP Far Behind: Report</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45790623/bitcoin-at-105000-bull-market-correction-or-bear-market-beginning">Bitcoin At $105,000: Bull Market Correction Or Bear Market Beginning?</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45788564/bitcoin-bull-run-on-the-brink-as-long-term-holders-accelerate-profit-taking-report">Bitcoin Bull Run On The Brink As Long-Term Holders Accelerate Profit-Taking: Report</a></li>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45779722/global-x-debuts-covered-call-bitcoin-etf-aims-to-keep-volatility-in-check">Global X Debuts Covered Call Bitcoin ETF, Aims To Keep Volatility In Check</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Jupiter (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">JUP</a>)</td>
<td>$0.4610</td>
<td>-14.5%</td>
</tr>
<tr>
<td>Raydium (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RAY</a>)</td>
<td>$2.06</td>
<td>-12.6%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001078&nbsp;&nbsp;</td>
<td>-11.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Kevin has been warning for weeks that Bitcoin is in a critical danger zone below $106,800. He urges traders to avoid overanalyzing and instead approach the market with maximum caution. This is not the time for false optimism, he stressed.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I have been warning everyone for weeks. Nothing should come as a surprise here. There was no point in over analyzing. It is a very simple layout here for <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> anything under the 106.8K level is danger zone and should be treated with maximum caution. I know it is not popular to… <a href="https://t.co/Eh8WOYlieY">pic.twitter.com/Eh8WOYlieY</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1930690365457313885?ref_src=twsrc%5Etfw">June 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a follow-up post, Kevin <a href="https://x.com/Kev_Capital_TA/status/1930693984512348488">outlined</a> two scenarios: 
Bearish case: A breakdown below $100,000–$103,000 could trigger a ~5% drop, aligning with the 0.5 Fib level and the daily super trend.
Bullish case: A reclaim of $106,800 would likely mark a scary but healthy retest, signaling a recovery.
He also flagged a key warning that multiple daily closes below $829 billion on Total 3 (altcoin market cap excluding BTC and ETH) would confirm a broader altcoin breakdown.
Crypto chart analyst Ali Martinez pointed out that Bitcoin's MVRV Ratio has slipped below its 200-day SMA, historically a sign of growing bearish momentum and elevated downside risk.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The MVRV Ratio just crossed below its 200-day SMA, a bearish signal that could point to further downside pressure for <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>. <a href="https://t.co/WQoewqd3m8">pic.twitter.com/WQoewqd3m8</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1930666425548444009?ref_src=twsrc%5Etfw">June 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Adding to the cautious tone, Rekt Capital <a href="https://x.com/rektcapital/status/1930687890880651632">noted</a> Bitcoin is now in a transitional phase, attempting a post-breakout retest of its re-accumulation range. Successfully holding this zone would confirm the shift into a new Price Discovery Uptrend (Phase 2). However, volatile deviations could occur before confirmation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45798988/could-bitcoin-plummet-to-90000-soon">Could Bitcoin Plummet To $90,000 Soon?</a></li>
</ul>
Photo Courtesy: Yalcin Sonat On Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$JUP

$PEPE

$RAY

$SHIB

$SOL

$WIF

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Dip Due To Macro Uncertainty – Bearish Signals Flash For BTC

<a href="https://www.bloomberg.com/news/articles/2025-06-05/peloton-ceo-says-he-has-no-interest-in-selling-the-company?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-05/peloton-ceo-says-he-has-no-interest-in-selling-the-company?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-05/peloton-ceo-says-he-has-no-interest-in-selling-the-company?srnd=homepage-americas</a>

PTON

'Peloton CEO Says He Has No Interest in Selling the Company' - Bloomberg News

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Alex Wright downgraded the rating for MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) from Buy to Hold and raised the price target from $2,450 to $2,800. MercadoLibre shares closed at $2,573.96 on Wednesday. <a href="https://www.benzinga.com/quote/MELI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Kaumil Gajrawala downgraded Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from Buy to Hold and raised the price target from $41 to $43. Chewy shares closed at $47.29 on Wednesday. <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Michael Zaremski downgraded Hamilton Insurance Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) from Outperform to Market Perform and maintained the price target of $23. Hamilton Insurance shares closed at $22.08 on Wednesday. <a href="https://www.benzinga.com/quote/HG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Kristen Owen downgraded Lavoro Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) from Outperform to Underperform. Lavoro shares closed at $2.54 on Wednesday. <a href="https://www.benzinga.com/quote/LVRO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Josh Baer downgraded the rating for Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) from Overweight to Equal-Weight and raised the price target from $10 to $11. Coursera shares closed at $9.36 on Wednesday. <a href="https://www.benzinga.com/quote/COUR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="620" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05152420/image-72-1024x620.png" alt="" class="wp-image-940292" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05152420/image-72-1024x620.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05152420/image-72-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05152420/image-72-768x465.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05152420/image-72.png 1071w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo via Shutterstock

Downgrades

CHWY

COUR

LVRO

MELI

This Hamilton Insurance Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

WIIM

CBRL

Cracker Barrel Old Country Store shares are trading lower after the company reported a Q3 sales miss.

<a href="https://www.bloomberg.com/news/articles/2025-06-05/openai-and-benchmark-are-backing-new-startups-from-ex-openai-staffers?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-05/openai-and-benchmark-are-backing-new-startups-from-ex-openai-staffers?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-05/openai-and-benchmark-are-backing-new-startups-from-ex-openai-staffers?srnd=homepage-americas</a>

MSFT

'OpenAI and Benchmark Back New Startups From Ex-OpenAI Staffers' - Bloomberg News

Macro Economic Events

Economics

Texas Stock Exchange CEO Reportedly Says It Costs Too Much For Companies To Go Public And To Remain Public; Says 35% Of Existing U.S.-Listed Public Companies Would Be Ineligible For Texas Listing; Says Chinese Cos That Do Not Meet The Basic U.S. Listing Standards Will Not Be Listed On The Exchange; Says Most New Primary Listings Will Come From Small, Mid-Cap Firms

Argan shares are trading higher after Lake Street raised its price target on the stock from $150 to $236.

ARLO

Arlo Technologies shares are trading higher after the company announced it has surpassed the $300 million annual recurring revenue milestone.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wedbush analyst David Nierengarten initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with an Outperform rating and announced a price target of $22. Telix Pharmaceuticals shares closed at $17.48 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Emma Schwartz initiated coverage on Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) with a Buy rating and announced a price target of $39. Excelerate Energy shares closed at $29.69 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Albert Lowe initiated coverage on Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy rating and announced a price target of $4. Atossa Therapeutics shares closed at $0.8571 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Joshua Pokrzywinski initiated coverage on Parker-Hannifin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with an Equal-Weight rating and announced a price target of $700. Parker Hannifin shares closed at $665.26 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth Capital analyst Boobalan Pachaiyappan initiated coverage on PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy rating and announced a price target of $9. PolyPid shares closed at $2.98 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-1024x580.png" alt="" class="wp-image-940280" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Initiation

ATOS

PYPD

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected" title="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected">https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected</a>.

Biotech

General

'Flexible Tracheostomy Tube Recall: Medtronic Removes Shiley Adult Flexible Tracheostomy Tube with TaperGuard Cuff Reusable Inner Cannula Due to Risk for Disconnection of the Flange from the Device Cannula' - FDA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Julien Dumoulin-Smith upgraded the rating for The Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Hold to Buy and lowered the price target from $102 to $100. Southern shares closed at $88.29 on Wednesday. <a href="https://www.benzinga.com/quote/SO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss upgraded Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from Neutral to Overweight and raised the price target from $72 to $111. Dollar Tree shares closed at $88.62 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Timothy Coffey upgraded the rating for Glacier Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBCI#NYSE">GBCI</a>) from Neutral to Buy and announced a $48 price target. Glacier Bancorp shares closed at $41.21 on Wednesday. <a href="https://www.benzinga.com/quote/GBCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Josh Baer upgraded Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) from Underweight to Equal-Weight and boosted the price target from $7 to $9. Udemy shares closed at $7.69 on Wednesday. <a href="https://www.benzinga.com/quote/UDMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Dan Dolev upgraded Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) from Neutral to Outperform and raised the price target from $359 to $425. Visa shares closed at $368.08 on Wednesday. <a href="https://www.benzinga.com/quote/V/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/V/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-1024x591.png" alt="" class="wp-image-940262" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Upgrades

Intraday Update

GBCI

UDMY

This Visa Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its single-shot <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">chikungunya vaccine</a>, Ixchiq, in 304 children, according to a press release. 
Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the company expects to initiate in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45797405/valneva-reports-positive-six-month-antibody-persistence-and-safety-phase-2-results-in-children-for" rel="noreferrer noopener">first quarter of 2026</a>.
The objective is to extend the product label to this age group.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45356303/us-health-agencies-recommend-pausing-valnevas-chikungunya-vaccine-for-older-adults-after-adverse-events" rel="noreferrer noopener">US Health Agencies Recommend Pausing Valneva&#8217;s Chikungunya Vaccine For Older Adults After Adverse Events</a>
Trial VLA1553-221&#8217;s six-month results were in line with the initial data the company reported for this trial in January 2025.
A full dose (licensed Ixchiq formulation and presentation) elicited a more robust immune response in children aged one to eleven years at Day 15 and Day 180 post-vaccination compared to a half dose.
Overall, the immunological response profile was in line with what was previously observed <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43102451/valneva-chikungunya-vaccine-shows-high-sustained-immune-response-in-adolescents-one-year-after-single-shot" rel="noreferrer noopener">in adults and adolescents</a>.
The strong immune response was confirmed in CHIKV-naïve children with a 96.5% seroresponse rate (full dose) at Day 180.
VLA1553 was well tolerated in children aged one to 11 years, regardless of the dose or previous CHIKV infection. No safety concerns were identified.
The comparability of the VLA1553 doses tested in terms of safety and tolerability, along with the more pronounced immune response of the full dose observed for all age groups tested in children up to Day 180 post-vaccination, support the selection of the full dose for use in this population.
Juan Carlos Jaramillo, chief medical officer of Valneva, said, &#8220;The six months persistence and safety data in children are aligned with the robust antibody response and safety profile we reported in adolescents after a single vaccination.&#8221;
In April, the Brazilian Health Regulatory Agency (ANVISA) granted marketing authorization to&nbsp;Valneva&#8217;s Ixchiq&nbsp;to prevent disease caused by the chikungunya virus in <a href="https://www.benzinga.com/general/biotech/25/04/44798557/brazil-approves-valnevas-mosquito-borne-chikungunya-vaccine" target="_blank" rel="noreferrer noopener">individuals&nbsp;18 and older</a>.
The ANVISA decision marks the world's first approval of a chikungunya vaccine in an endemic country.
VALN Price Action: VALN stock is up 0.49% at $6.28 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45790700/honeywells-saf-alliance-targets-massive-renewable-output-to-power-100000-homes" target="_blank" rel="noreferrer noopener">Honeywell&#8217;s SAF Alliance Targets Massive Renewable Output To Power 100,000 Homes</a></li>
</ul>
Photo: Shutterstock

Health Care

Global

VALN

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-baxter-issues-correction-novum-iq-large-volume-pump-due-potential#:~:text=Medical%20Device%20Recalls-,Infusion%20Pump%20Correction%3A%20Baxter%20Issues%20Correction%20for%20Novum%20IQ%20Large,due%20to%20Potential%20for%20Underinfusion&amp;text=This%20recall%20involves%20correcting%20certain,as%20the%20most%20serious%20type" title="https://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-baxter-issues-correction-novum-iq-large-volume-pump-due-potential#:~:text=Medical%20Device%20Recalls-,Infusion%20Pump%20Correction%3A%20Baxter%20Issues%20Correction%20for%20Novum%20IQ%20Large,due%20to%20Potential%20for%20Underinfusion&amp;text=This%20recall%20involves%20correcting%20certain,as%20the%20most%20serious%20type">https://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-baxter-issues-correction-novum-iq-large-volume-pump-due-potential#:~:text=Medical%20Device%20Recalls-,Infusion%20Pump%20Correction%3A%20Baxter%20Issues%20Correction%20for%20Novum%20IQ%20Large,due%20to%20Potential%20for%20Underinfusion&amp;text=This%20recall%20involves%20correcting%20certain,as%20the%20most%20serious%20type</a>.

'Infusion Pump Correction: Baxter Issues Correction for Novum IQ Large Volume Pump due to Potential for Underinfusion' - FDA

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally in 2025 has been nothing short of stratospheric, with <a href="https://www.benzinga.com/crypto">the flagship crypto</a> blowing past the $100,000 mark and dreams of $200,000 swirling in the digital air. 
While bulls are eyeing the moon, two publicly traded names &#8211; MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) &#8211; are catching serious wind from the crypto updraft. But can they stay aloft, or are they flying too close to the sun?
<h2 class="wp-block-heading">MicroStrategy: Saylor's Billion-Dollar Crypto Binge</h2>
Michael Saylor has turned MicroStrategy from a business intelligence firm into a full-throttle Bitcoin proxy. With a stash of 580,250 BTC now worth $40.6 billion, the company's fate is fused to the price of Bitcoin. The latest move? 
A cool $427 million plowed into 4,020 more coins at $106,000 each. Forget quarterly reports &#8211; MSTR&#8217;s main KPI is BTC/USD.
The math is as wild as the strategy: if Bitcoin hits $150,000, MSTR could touch $2,000 per share. At $200,000? Expect targets of $3,500 and a Saylor victory lap. But there's turbulence too. 
When BTC dipped in late 2024, MSTR shed 30% in days. With short interest ballooning past $10 billion and critics warning the market cap now dwarfs Coinbase despite a fraction of its revenue, the stock looks less like a rocket and more like a loaded powder keg.
Read Also: <a href="https://www.benzinga.com/markets/offerings/25/06/45785682/chamath-palihapitiya-says-circle-ipo-valued-at-7-billion-means-its-a-genius-buy-for-coinbase-heres-why" target="_blank" rel="noreferrer noopener">Chamath Palihapitiya Says Circle IPO Valued At $7 Billion Means It&#8217;s A &#8216;Genius&#8217; Buy For Coinbase, Here&#8217;s Why</a>
<h2 class="wp-block-heading">Coinbase: The Middleman Minting Money</h2>
Coinbase, on the other hand, is the infrastructure play &#8211; less glam, more grit. It isn't chasing Bitcoin highs with treasury funds, but instead cashing in on trading fees, ETF custodianship, and its expanding Base blockchain. It's the backstage pass to the crypto show.
When Trump's pro-crypto win sent BTC flying, COIN popped 36%. A modest January bump followed Bitcoin's 2% move. Analysts like the stability. With a <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">consensus Buy rating</a> and growing ETF ties &#8211; $15 billion AUM inflows and counting &#8211; Coinbase is well-positioned for the long haul. Its $1 billion buyback announced last year is a cherry on top.
Still, Coinbase&#8217;s minimal Bitcoin holdings draw jabs from purists. But while MicroStrategy swings for home runs, Coinbase is playing the long game &#8211; consistent, diversified, and quietly raking in the chips.
<h2 class="wp-block-heading">Final Byte</h2>
Bitcoin's surge is minting winners &#8211; and MicroStrategy and Coinbase are riding different boards on the same crypto wave. 
One's a high-wire act with billions in BTC on the line. The other? A steady surfboarder cashing in on every wave.
Whether Bitcoin touches $200,000 or hits an air pocket, these two remain at the epicenter of crypto's most electrifying moment.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45798988/could-bitcoin-plummet-to-90000-soon">Could Bitcoin Plummet To $90,000 Soon?</a></li>
</ul>
Photo: Shutterstock

Long Ideas

COIN

MSTR

Bitcoin's Moonshot: Can MicroStrategy And Coinbase Keep Riding The Crypto Wave?

<a href="https://www.wsj.com/politics/policy/senate-republicans-seek-to-protect-nasa-programs-targeted-for-cuts-d7cc4415" title="https://www.wsj.com/politics/policy/senate-republicans-seek-to-protect-nasa-programs-targeted-for-cuts-d7cc4415">https://www.wsj.com/politics/policy/senate-republicans-seek-to-protect-nasa-programs-targeted-for-cuts-d7cc4415</a>

Politics

'Senate Republicans Seek to Protect NASA Programs Targeted for Cuts' - WSJ

Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) shares are trading lower Thursday after the company released <a href="https://www.benzinga.com/pressreleases/25/06/g45780640/costco-wholesale-corporation-reports-may-sales-results">its May sales report</a>.
What To Know: For the four-week period ending June 1, 2025, Costco reported net sales of $20.97 billion, up 6.8% from $19.64 billion a year earlier. For the first 39 weeks of the fiscal year, total net sales reached $201.02 billion, an 8% increase compared to $186.07 billion last year.
Comparable sales rose 4.3% for May across the company. In the U.S., comparable sales were up just 4.1%, while international markets like Canada and other regions rose 3.3% and 6.6%, respectively. E-commerce continued to show stronger growth, up 11.6% for the month.
Stripping out the effects of gasoline prices and foreign exchange, comparable sales were stronger, 6% for the total company, including 5.5% in the U.S. and 12% in e-commerce. However, even those numbers didn't prevent the stock from falling sharply.
One reason for the selloff may be that U.S. same-store sales growth, while positive, lagged behind inflation and didn&#8217;t show a major acceleration. Gross margin and membership revenue details weren't included in the May report, leaving gaps in the picture of overall profitability and operational efficiency. Inventory and cost pressures, common issues in the retail sector, may also be on investors&#8217; minds.
Costco's sharp drop in share price suggests the market may have been expecting more aggressive growth, especially given the stock's high valuation. Despite strong year-to-date performance, the nearly 4% decline indicates that investors are looking beyond top-line growth and focusing on margin trends, U.S. consumer demand and the broader retail environment.
COST Price Action: Costco shares were down 4.01% at $1009.47 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45798808/trump-announces-china-trade-talks-tesla-stock-slumps-whats-driving-markets-thursday">Trump Announces China Trade Talks, Tesla Stock Slumps: What&#8217;s Driving Markets Thursday? </a></li>
</ul>
Image Via Shutterstock.

Movers

COST

Costco Stock Falls Nearly 4% After May Sales Report Despite Solid Growth

Investors with a lot of money to spend have taken a bearish stance on Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Axon Enterprise.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $62,160, and 7, calls, for a total amount of $839,022.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $350.0 and $920.0 for Axon Enterprise, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Axon Enterprise's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axon Enterprise's whale activity within a strike price range from $350.0 to $920.0 in the last 30 days. 
<h3>Axon Enterprise Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749150192_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$44.9</td>
<td>$42.0</td>
<td>$42.0</td>
<td>$750.00</td>
<td>$504.0K</td>
<td align="right">467</td>
<td align="right">121</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$43.0</td>
<td>$41.7</td>
<td>$42.0</td>
<td>$750.00</td>
<td>$126.0K</td>
<td align="right">467</td>
<td align="right">151</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$212.0</td>
<td>$207.2</td>
<td>$207.2</td>
<td>$920.00</td>
<td>$62.1K</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$107.8</td>
<td>$104.8</td>
<td>$107.8</td>
<td>$730.00</td>
<td>$53.9K</td>
<td align="right">55</td>
<td align="right">5</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$447.4</td>
<td>$438.9</td>
<td>$442.72</td>
<td>$350.00</td>
<td>$44.2K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions. The company's suite includes cloud-hosted digital evidence management solutions, productivity and real-time operations software, body cameras, in-car cameras, TASER energy devices, drones and robotic security, and training solutions. The company's operation comprises of two operating segments, Software and Sensors, and TASER. The company generates the majority of its revenue from the Software and Sensors segment, which is engaged in developing, manufacturing, and selling fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Having examined the options trading patterns of Axon Enterprise, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Axon Enterprise's Current Market Status</h3>
<ul>
<li>With a volume of 347,348, the price of AXON is up 0.76% at $785.96. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<h3>What Analysts Are Saying About Axon Enterprise</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $802.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Axon Enterprise, which currently sits at a price target of $895. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Axon Enterprise with a target price of $830. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Axon Enterprise, which currently sits at a price target of $750. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Axon Enterprise, which currently sits at a price target of $735. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Axon Enterprise, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

AXON

Axon Enterprise's Options: A Look at What the Big Money is Thinking

Small Cap

Press Releases

Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital

Contracts

Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center

Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients

Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives

Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

IINN

Litchfield Hills

Aegis Capital

Inspira Technologies shares are trading higher after the company announced it is scaling up production of its FDA-cleared INSPIRA ART100 system in response to anticipated demand from a European governmental authority.

Comments

Inspira Technologies Oxy

Actualités

Dernières nouvelles pour Inspira Technologies Oxy (NASDAQ:IINN) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL